The aim of PLUS is to conduct a multi-centre, blinded, randomised, controlled trial (RCT) to
determine whether fluid resuscitation and therapy with a "balanced" crystalloid solution
(Plasma-Lyte 148®) decreases 90-day mortality in critically ill patients requiring fluid
resuscitation when compared with the same treatment using 0.9% sodium chloride (saline)
Phase:
Phase 4
Details
Lead Sponsor:
The George Institute
Collaborators:
Australian and New Zealand Intensive Care Society Clinical Trials Group Baxter Healthcare Corporation